Nona Biosciences and Pfizer Have Entered Into a Worldwide License Agreement for HBM9033, an Antibody-drug Conjugate (ADC) Targeting MSLN

Nona Biosciences, a global biotechnology company specializing in a comprehensive "Idea to IND" (I to ITM) solution covering target validation, antibody discovery, and preclinical research, has recently disclosed an exclusive license agreement with Pfizer Inc. This collaboration focuses on the global clinical development and commercialization of Nona Biosciences' antibody-drug conjugate (ADC), HBM9033, which targets MSLN.

According to the agreement's terms, Nona Biosciences is set to receive up to $53 million in upfront and near-term payments, with the potential for additional payments reaching up to $1.05 billion upon achieving specific development and commercial milestones. Additionally, Nona Biosciences stands to earn tiered royalties on net sales ranging from high single digits to high teens.

Expressing enthusiasm about the collaboration with Pfizer, Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences, highlighted Pfizer's commitment to developing impactful cancer medicines. Wang sees this agreement as a significant milestone for Nona Biosciences, showcasing the advancement of their proprietary Harbour Mice® platform and the ADC ecosystem. This partnership with Pfizer expands Nona's global network of collaborations, strengthening the scientific and commercial value of their technology platforms.

HBM9033, the focal point of this collaboration, is an ADC drug designed to target human MSLN, a tumor-associated antigen found in various solid tumors. The fully human monoclonal antibody (mAb) in HBM9033, derived from the Harbour Mice® platform, exhibits well-tuned properties, demonstrating reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. This unique design ensures superior potency and safety in diverse preclinical tumor models with varying MSLN expression levels, positioning HBM9033 as a potential globally leading therapeutic option.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!